Eric King, DO
Interventional Cardiology · Bellingham, WANPI 1700083409
Payments from drug & device makers
Across 28 payments — averaging $62.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Cardinal Health 200 LLC$163
- Edwards Lifesciences$49
- Johnson & Johnson$46
- AstraZeneca$39
- Terumo Medical Corporation$39
- plus $59 from 5 others
What the payments were for
- Travel & lodging$1,18968%
- Food & beverage$53831%
- Education$332%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 13 | $1,367 |
| Cardinal Health 200 LLC | 3 | $163 |
| Edwards Lifesciences | 1 | $49 |
| Johnson & Johnson | 2 | $46 |
| AstraZeneca | 2 | $39 |
| Terumo Medical Corporation | 2 | $39 |
| Kestra Medical Technology Services, Inc. | 1 | $23 |
| Chiesi USA, Inc. | 1 | $18 |
| Abiomed | 1 | $14 |
| Merit Medical Systems Inc | 1 | $4 |
| Cardiovascular Systems Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip System$1,170
How this compares
$1,760 in reported general payments places this provider in the 30th percentile of 125 interventional cardiology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 33 | $35,459 |
| EliquisApixaban | 16 | $17,905 |
| Ranolazine ErRanolazine | 17 | $1,094 |
| ClopidogrelClopidogrel Bisulfate | 30 | $775 |
| Carvedilol | 56 | $676 |
| Atorvastatin Calcium | 39 | $646 |
| Losartan Potassium | 51 | $585 |
| Metoprolol Succinate | 41 | $584 |
| Rosuvastatin Calcium | 21 | $407 |
| Lisinopril | 26 | $287 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 15 | $195 |
| Warfarin Sodium | 17 | $182 |
| Furosemide | 17 | $100 |
| Amlodipine Besylate | 24 | $79 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Bellingham
- Jimmy YeeBellingham$5K
- Sameer GafoorSeattle$2M
- James McCabeSeattle$1.7M
- William LombardiSeattle$1.2M
- Sidakpal PanaichSeattle$1.2M
- Kathleen KearneySeattle$802K
- Ming ZhangSeattle$693K
- Robert RileyBellevue$652K
- Mahesh MulumudiEverett$569K
- Danny DvirSeattle$380K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.